Neurotrope (NTRP) Stock Price, News & Analysis

Company Overview

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Key Stats

• Today's Range: $2.99 to $3.08
• 50-Day Range: $0.92 to $1.05
• 52-Week Range: $0.68 to $3.85
• Volume: 4,247 shs
• Average Volume: 8,178 shs
• Market Capitalization: $4.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NTRP Stock Analysis - Frequently Asked Questions

How were Neurotrope's earnings last quarter?

Neurotrope, Inc. (NASDAQ:NTRP) issued its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. Neurotrope had a negative trailing twelve-month return on equity of 241.03% and a negative net margin of 1,598.05%.

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Alibaba Group (BABA), Zevra Therapeutics (KMPH), Sorrento Therapeutics (SRNE) and Pieris Pharmaceuticals (PIRS).

Company Calendar

• Last Earnings: 10/30/2018
• Today: 9/20/2024
• Next Earnings (Estimated): 9/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Discretionary
• Industry: Transportation services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NTRP
• CUSIP: N/A
• CIK: 1513856
• Web: www.neurotropebioscience.com
• Phone: 973-242-0005
• Fax: 505-424-3174
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($10.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,330,000.00
• Net Margins: -1,598.05%
• Pretax Margin: -1,450.33%
• Return on Equity: -241.03%
• Return on Assets: -175.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.87
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: $460,000.00
• Price / Sales: 8.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.01 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 704,000
• Market Cap: $4.10 million
• Optionable: No Data
• Beta: 1.60